A randomized, double-blind, placebo-controlled phase II study (MOT114479) to evaluate the safety and efficacy and dose response of 28 days of orally administered camicinal, a motilin receptor agonist, in diabetics with gastroparesis

Authors
Category Primary study
JournalGastroenterology
Year 2014
This article has no abstract
Epistemonikos ID: c925a5c32e319d868983f81851e736a7c7235144
First added on: Feb 06, 2025